MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

Míreanna comhchosúla

• Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test
  de réir: Yoshihiro Miyashita, MD, et al.
  Foilsithe / Cruthaithe: (2024-06-01)
• Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
  de réir: Shinkichi Takamori, et al.
  Foilsithe / Cruthaithe: (2021-03-01)
• Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
  de réir: Go Makimoto, et al.
  Foilsithe / Cruthaithe: (2022-05-01)
• Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
  de réir: Kei Kunimasa, et al.
  Foilsithe / Cruthaithe: (2021-12-01)
• Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
  de réir: Yukihiro Umeda, et al.
  Foilsithe / Cruthaithe: (2025-01-01)